Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Genomic Characteristics of Cell-Free DNA Associated With Enzalutamide Treatment in Castration-Resistant Prostate Cancer
- Safety and Anti-Tumor Activity of Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer
- Letrozole With or Without Bevacizumab for Hormone Receptor–Positive Advanced-Stage Breast Cancer
- Effects of ER and HER2 Levels on the Efficacy of Trastuzumab
- Longitudinal Adverse Event Assessment in Oncology Clinical Trials
- Adjuvant Endocrine Therapies for Premenopausal Women With HR+ HER2− Early Breast Cancer
- Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
- FDG-PET/CT in Suspected Recurrent Breast Cancer
- Fertility Preservation in Patients With Breast Cancer
- Atezolizumab vs Docetaxel for Patients With Previously Treated Non–Small Cell Lung Cancer